Condition: Sjogrens Disease · Idiopathic Inflammatory Myopathy (IIM) · Sponsor: Lakefront Biotherapeutics West LLC
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
This description comes directly from the study's public registry record.
Study Sponsor · 415-429-4887 · clinical@ouromeds.com
Always discuss trial participation with your own doctor first.
| Waikato Hospital | Hamilton, Waikato Region, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07229144